Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2007

BG Medicine Commences Investigation for Biomarkers of Hepatotoxicity

  • BG Medicine reports that the FDA approved the first phase of the Liver Toxicity Biomarker Study (LTBS). This discovery project aims at finding biomarkers related to human hepatotoxicity in standard preclinical tests.

    It will be conducted under a CRADA with the FDA’s National Center for Toxicological Research (NCTR), as part of FDA’s Critical Path Initiative.

    The scientific advisory board will consist of seven pharmaceutical companies—Pfizer, Johnson & Johnson Pharmaceutical Research and Development, Mitsubishi Chemical Holdings, Orion, UCB, Sankyo, and Eisai—providing project funding.

    Additionally, Applied Biosystems will supply biomarker discovery systems based on mass spectrometry, including service, support, and in-kind contributions.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »